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Ovarian cancer is the leading cause of death from gynaecological
malignancy in the UK, with over 4000 women dying annually. The
high mortality is attributable to the lack of effective screening
strategies and the fact that early-stage disease remains clinically
silent. Most patients present with advanced disease, for which the
long-term survival remains <30%. However, if early stage disease
could be detected the 5-year survival could rise to 80–95% (Berek,
1994). Current ovarian cancer screening methods using serum
tumour markers and ultrasound/Doppler techniques lack the speci-
ficity to achieve this goal at present.
Nucleic acid-based molecular detection methods have been
used to demonstrate the presence of tumour cells in samples of
stool (Sidransky et al, 1992), urine (Mao et al, 1996), sputum
(Mao et al, 1994) and blood (Smith et al, 1991). In addition, the
same approaches have confirmed the presence of free circulating
tumour DNA in the serum of patients with epithelial tumours of
the lung (Chen et al, 1996), head and neck (Nawroz et al, 1996)
and colon (Hibi et al, 1998). The majority of these studies have
demonstrated clear clonality between the genetic alterations
observed in test samples and the corresponding primary tumour
material. The types of alteration recorded have included specific
gene mutations, loss of heterozygosity (LOH) and microsatellite
instability (MI).
Only 5–10% of ovarian carcinomas appear to involve a familial
predisposition. The two major syndromes involved are the familial
breast and ovarian cancer syndrome, associated with inherited
mutations in the BRCAl gene, and the Lynch II syndrome
(HNPCC), associated with inherited defects in the DNA mismatch
repair system. Abnormalities associated with sporadic forms of the
disease include mutations in k-ras and p53 genes, and changes in
expression of HER-2 (Gallion et al, 1995). Allelotyping studies
have identified common sites of LOH on chromosomes 5q, 6q,
11p, 13q, 14q, 15q, 18q, Xp (Cliby et al, 1993; Osborne and
Leech, 1994), and particularly on chromosome 7q (Zenklusen
et al, 1995), 9q (Schultz et al, 1995) and 17p (Phillips et al, 1993).
The occurrence of novel alleles at microsatellite loci, due to either
a replication error phenotype (RER+) resulting from defective
mismatch repair or general genetic instability, has been described
in 17–37% of ovarian tumours (Fujita et al, 1995; King et al, 1995;
Sood and Buller, 1996). However, MI may occur in up to 75% of
stage I ovarian tumours, and 71% of uncommon histopathological
types such as endometrioid or mixed serous and mucinous
tumours (King et al, 1995).
We obtained serum and peritoneal fluid from 20 women with
epithelial ovarian carcinoma, and used a panel of six polymorphic
microsatellite markers to detect LOH or novel alleles in the DNA
extracted from the samples. The same analysis was carried out on
tumour tissue microdissected from paraffin sections of the primary
tumour from each case. The aim of this study was to establish
whether tumour-specific biomarkers could be detected in the
serum and peritoneal fluid of ovarian cancer patients, particularly
those with early-stage disease.
MATERIALS AND METHODS
Sample collection
Samples were collected from 20 women undergoing laparotomy
for ovarian cancer, and eight women with benign or physiological
cysts. None of the women were known to carry a familial
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Correspondence to: PA Burnspredisposition for ovarian cancer, although one woman had a first-
degree relative with breast cancer. The cancer cases included six
stage Ia and 14 stage II–IV cases. In all six of the stage Ia cases
total abdominal hysterectomy, bilateral salpingo-oopherectomy,
omentectomy and peritoneal washings for cytology were taken,
while ipsilateral pelvic node resection and para-aortic node
sampling was carried out in three of the six. The pathological
staging, serum CA125 and cytology results are shown in Table 1.
DNA extraction
Normal DNA
Ten millilitres of blood were taken into heparinized tubes, and 1
ml was used for extraction of white blood cell DNA using Nucleon
(Scotlab).
Serum DNA
Ten millilitres of blood was taken, allowed to clot and then
centrifuged at 1300 g. The serum supernatant was frozen at –80°C
in aliquots and DNA was extracted from 400 ml using DNAzol
(Gibco BRL).
Peritoneal fluid DNA
At laparotomy, 20 ml of ascitic fluid or pelvic peritoneal washings
were taken, of which 10 ml were sent for routine cytological
analysis, and the other 10 ml for molecular analysis. The latter
samples were centrifuged at 1300 g to pellet any cells, which were
washed twice in phosphate-buffered saline (PBS). The cells were
frozen at –80°C in tissue culture-freezing medium (2.75 ml
Dulbecco’s modified Eagle’s medium, 1.25 ml fetal calf serum,
1 ml dimethyl sulphoxide (DMSO)) in 1 ml aliquots. Cells were
spun out of thawed aliquots and washed twice with 5 ml PBS to
remove DMSO. Epithelial cells were then harvested by immuno-
magnetic separation using Dynabeads coated with the epithelial
specific antibody Ber EP4 (Dynal UK). DNA was extracted from
the cells using Dynabeads DNA Direct (Dynal UK). A peritoneal
fluid sample from patient 065 was unavailable for molecular
analysis.
Tumour DNA
Areas of tumour tissue were microdissected from ten paraffin
sections of primary tumours and DNA extracted using Nucleon
(Scotlab). The precipitated DNA was resuspended in 50 ml of
water.
Cyst wall DNA
For cases of benign and physiological cyst, areas corresponding to
the cyst wall were microdissected and processed in the same way
as the tumour DNA.
Microsatellite analysis
Polymerase chain reaction (PCR) amplification was carried out
using oligonucleotide amplimers specific for six polymorphic
DNA microsatellite loci:
DP1 (D5S346) on 5q (Spirio et al, 1993)
486 (D7S486) on 7q (Gyapay et al, 1994)
522 (D7S522) on 7q (Gyapay et al, 1994)
D11 (D11S904) on 11p (Gyapay et al, 1994)
p53V (intron1 in p53) on 17p (Cawkwell et al, 1994)
BRCA1 (D17S855) on 17q (Gao et al, 1995).
The chosen markers map to regions which commonly display
LOH in ovarian carcinomas. One amplimer from each pair was
fluorescently labelled using the dye-amidite method (Cawkwell
et al, 1994).
The PCR reactions were set up in 25 ml of 1 ´ SuperTaq
Reaction Buffer (HT Biotechnology Ltd) containing 200 mM
dNTPs, 12.5 pmol of each amplimer, 1.5–6.0 mM magnesium
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Table 1 Staging, pathology, cytology and genetic analysis of ovarian cancer patients
Patient Stagea Histology type and differentiation Cytologyb Tumour Serum Peritoneal fluid
LOHc MId LOH MI LOH MI
112 Ia Endometrioid, Grade 1 – 1/6 – 2/6 – 0/6 –
200 Ia Endometrioid and mucinous, Grade 2 – 1/5 – 0/5 – 0/5 –
3775 Ia Mucinous, Grade 2 – 0/1 5 0/4 1 0/4 1
4224 Ia Mucinous, Grade 2 – 0/3 2 0/3 2 0/3 2
5475 Ia Serous, Grade 2 – 3/4 – 2/4 – 0/4 –
065 Ia Endometrioid, Grade 1 – 1/3 1 2/3 1 NA –
705 IIc Serous, Grade 3 + 1/5 – 1/5 – 1/4 –
488 IIIc Serous, Grade 3 + 2/3 – 2/3 – 2/3 –
165 IIIc Papillary serous, Grade 2 – 3/3 – 3/3 – 1/3 –
231 IIIc Papillary serous, Grade 2 – 4/5 – 2/5 – 1/5 –
042 IIIc Serous, Grade 3 – 5/5 1 2/5 – 0/5 –
285 IIIc Papillary serous, Grade 3 – 3/4 – 1/4 – 1/4 –
577 IIIc Endometrioid & serous, Grade 3 + 0/4 – 2/4 – 1/4 –
0776 IIIc Papillary serous, Grade 3 + 0/3 – 1/3 – 0/3 –
9930 IIIc Serous, Grade 3 – 5/5 – 3/5 – 5/5 –
4992 IIIc Papillary serous, Grade 3 – 2/4 – 2/4 – 1/4 –
5042 IIIc Endometrioid, Grade 3 + 2/5 – 0/5 – 0/5 –
3944 IIIc Serous, Grade 3 – 0/4 – 1/4 – 0/4 –
4571 IIIc Papillary serous, Grade 3 + 3/4 – 1/4 – 2/3 –
421 IV Endometrioid, Grade 3 + 3/4 – 0/4 – 3/4 –
Total 39/80 9 27/83 4 18/78 3
a FIGO staging of primary tumour; bpresence of malignant cells in ascitic fluid or peritoneal washings; cproportion of informative (heterozygous) markers
displaying loss of heterozygosity (LOH); dmicrosatellite instability. NA, not available for molecular analysis.chloride (optimized for each pair of amplimers), and 1 ml of DNA.
After denaturing at 95°C for 3 min and a pause at 80°C to add
0.5 U of SuperTaq polymerase (HT Biotechnology Ltd), the DNA
was amplified using a programme of 92°C for 30 s, 56°C for
1 min, 72°C for 30 s, for a total of 35 cycles. The amplification
products were visualized by agarose gel electrophoresis to esti-
mate yield, electrophoresed on an ABI 373A DNA Sequencer
(Applied Biosystems), and analysed using Genescan Analysis
Software (Applied Biosystems), which determines the size of
the PCR products and the amount of fluorescent signal. Suitable
dilutions of PCR products were run to ensure that band intensities
fell within the linear portion of the fluorescence detection range
(500–4000).
Optimizing template DNA for PCR
We found that significantly different allele ratios could be obtained
in our PCR reactions with different amounts of starting template
DNA. It is difficult to accurately quantify the amount of DNA
actually available for PCR amplification in a small sample. It was
therefore essential to use different dilutions of normal control
DNA (down to 1 ´ 10–4) and choose the dilution which produced a
comparable yield, as estimated by agarose gel electrophoresis, to
that of the tumour/serum/peritoneal fluid samples as the control
lane for Genescan analysis.
LOH and MI
The use of Genescan software and multiple PCR runs allowed us
to accurately measure alterations in allele ratios. LOH was defined
as a >20% shift in allele ratios (see below), as calculated using the
equation T1:T2/N1:N2 (where T1:T2 is the ratio of the two tumour
alleles and N1:N2 is the ratio of the corresponding normal alleles).
Novel alleles were defined as one or more novel peaks consistent
in size with expansion or contraction of the microsatellite repeat
and distinct from PCR stutter products. All LOHs or MIs were
confirmed by multiple independent PCR amplifications.
RESULTS
Defining parameters for LOH
An important consideration in studies which look for LOH in
tumour DNA is deciding what constitutes a significant shift in
allele ratio at heterozygous loci. The use of Genescan Analysis
software allowed us to accurately compare allele ratios from
tumour, peritoneal fluid and serum DNA samples, with those
obtained from normal DNA. Analysis of over 250 of these
comparisons revealed a clear bimodal distribution, with 99% of
values falling between 0 and 80% or 85 and 100% (data not
shown), with a striking gap between 80 and 85%. On this basis we
assumed that an allele ratio shift of 0–15% represented normal
variation in the amplification of alleles present in equimolar
amounts in normal diploid DNA, whereas a shift of >20% repre-
sented a notable deviation from a balanced allele ratio. For the
purposes of this study we therefore chose a >20% shift as the
criteria for defining LOH in our samples. However, most allelo-
typing studies using microdissected paraffin-embedded tumour
material tend to use a >50% shift to define LOH. We therefore also
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Figure 1 Electropherograms of microsatellite instability (MI) or loss of heterozygosity (LOH) in three ovarian cancer patients. Fluorescently labelled PCR
products were run on an ABI 373A DNA Sequencer. The fluorescent signals were converted into electropherograms by Genescan Software. Length of product
in base pairs is indicated on the X-axis and an arbitrary measurement of peak height, proportional to signal intensity, on the Y-axis. (A) MI at p53V locus seen in
patient 4224; (B) LOH at the D7S486 locus seen in patient 165; (C) LOH at the D5S346 (DP1) locus seen in patient 4571. N, normal DNA; T, tumour DNA; S,
serum DNA; P, peritoneal fluid DNAanalysed our results using a >50% shift in allele ratio as the criteria
for LOH (see below).
LOH and MI in primary tumour
All of the primary tumours displayed at least one genetic alteration
(Figure 1A–C), with the exception of patients 577, 0776 and 3944
(Table 1). LOH was detected at 39/80 (49%) informative markers,
and was twice as common in stage II–IV (33/58, 57%) as in stage
Ia tumours (6/22, 27%). LOH occurred most frequently at BRCA1
on chromosome 17q (63%), DP1 on 5q (56%) and D11 on 11p
(53%) (Table 2).
Novel alleles were observed in the primary tumours of 3/6 stage
Ia patients (3775, 4244, 065), but only in 1/14 patients (042) with
more advanced disease (Tables 1 and 2). In the case of patients
3775 (novel alleles at 5/6 loci) and 4224 (2/6) this may be
evidence of an RER+ phenotype associated with mismatch repair
deficiency.
LOH and MI in serum DNA
Genetic alterations were detected in 17/20 serum DNA samples,
including 5/6 of the samples from patients with stage Ia disease
(Table 1). LOH was harder to detect in serum (27/83 or 33% of
markers) than in the primary tumours (49%). Of the 27 cases of
LOH detected in serum, 19 (73%) were observed in the corre-
sponding primary tumour (Figure 1B,C) and eight were specific to
the serum DNA (Table 2). Thus 19/39 (49%) examples of LOH
found in primary tumours were detectable in serum DNA.
Novel alleles were harder to detect in serum DNA than in
primary tumour DNA (Table 1). Of the nine examples found in
primary tumours, four were detected in the corresponding serum
samples (Table 2 and Figure 1A). The three patients with novel
alleles in their serum DNA all had stage Ia disease (Table 1).
LOH and MI in peritoneal fluid DNA
Only 12 of the 19 DNA samples extracted from peritoneal fluid
exhibited genetic alterations, and only 18/78 (23%) heterozygous
markers displayed LOH compared to 33% in the serum samples
and 49% in the primary tumours (Table 1). However, 17 of the 18
examples of LOH in the peritoneal fluid samples were also found
in the corresponding primary tumour (Figure 1B,C), indicating a
higher degree of clonality than was seen with the serum samples
(Table 2).
Novel alleles were detected in peritoneal fluid DNA from two
of the stage 1a patients, all of which had been observed in the
primary tumour and serum from the same patients (Table 2 and
Figure 1A). By definition, these two patients had negative peri-
toneal fluid cytology.
Reanalysis of results using >50% in allele ratios
Out of 84 examples of LOH featured in Table 1, 60 displayed
>50% shift in allele ratio. Of the remaining 24, which showed a
20–50% shift, 19 coincided with the finding of a >50% shift in
another sample from the same patient. For example, the serum
sample from patient 4571 showed a 30% reduction in the shorter
allele at marker DP1 (Figure 1C), whereas the tumour and peri-
toneal fluid samples showed almost complete loss. These observa-
tions of significant (P < 0.001) clonal similarity support our initial
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Table 2 Results of Genescan analysis of PCR products from 20 ovarian
cancer patients analysed for LOH or microsatellite instability at six
microsatellite loci
Patient Sample DP1 522 486 D11 P53 BRCA1
112 Tumour l l l l l l l l l l l
Serum l l l l l l lll l
Per. fluid l l l l l l l l l l l l
200 Tumour l l l l l l l l ´ l
Serum l l l l l l l l ´ l l
Per. fluid l l l l l l l l ´ l l
3775 Tumour MI MI MI MI MI l l
Serum l l l l l l MI ´ l l
Per. fluid l l l l l l MI ´ l l
4224 Tumour l l ´ l l MI MI l l
Serum l l ´ l l MI MI l l
Per. fluid l l ´ l l MI MI l l
5475 Tumour l ´ l l ll´
Serum l ´ l l l l l ´
Per. fluid l l ´ l l l l l l ´
065* Tumour l MI ´ l l l l ´
Serum l MI ´ l l l ´
705 Tumour l l l l l l l l ´ l
Serum l l l l l l l ´ l l
Per. fluid NP l l l l l l ´ l
488 Tumour ´´ l l l ´ l
Serum ´´ l l l ´ l
Per. fluid ´´ l l l ´ l
165 Tumour ´ ll ´ l ´
Serum ´ ll ´ l ´
Per. fluid ´ l l l ´ l l ´
231 Tumour l ´ l l lll
Serum l ´ l l l l l l l
Per. fluid l l ´ l l l l l l l
042 Tumour llll MI l
Serum l l l l l l ´ l l
Per. fluid l l l l l l l l ´ l l
285 Tumour l l ´ ll´ l
Serum l l ´ l l l l ´ l
Per. fluid l l ´ l l l l ´ l
577 Tumour l l ´´l l l l l l
Serum l l ´´l l l l
Per. fluid l l ´´l l l l l
0776 Tumour l l ´ l l l l ´´
Serum l l ´ l l l ´´
Per. fluid l l ´ l l l l ´´
9930 Tumour llll´ l
Serum llll l ´ l l
Per. fluid llll´ l
4992 Tumour l ´´l l l l l
Serum l ´´l l l l l
Per. fluid l ´´l l l l l l
5042 Tumour l l l l l l l ´ l
Serum l l l l l l l l ´ l l
Per. fluid l l l l l l l l ´ l l
3944 Tumour ´ l l l l l l ´ l l
Serum ´ l l l l l ´ l l
Per. fluid ´ l l l l l l ´ l l
4571 Tumour l ´ l l l ´ l
Serum l ´ l l l l ´ l l
Per. fluid l ´ l l NP ´ l
421 Tumour l l l ´ l ´ l
Serum l l l l ´ l l ´ l l
Per. fluid l l l ´ l ´ l
l l – heterozygosity retained; l – loss of heterozygosity; MI – microsatellite
instability; ´ – non-informative; NP – no product was obtained from repeated
PCR amplifications. *No peritoneal fluid sample was available for molecular
analysis from this patient. Per. fluid, peritoneal fluidassumption that a >20% shift represents a genuine case of LOH.
However, taking a >50% shift as the criteria for LOH we would
still have detected tumour-specific alterations in 5/6 serum
samples from stage Ia patients but only 7/14 stage II–IV patients.
In the case of peritoneal fluid we would still have detected alter-
ations in 2/5 stage Ia samples, and 8/14 stage II–IV samples
(reduced from 10/14).
LOH and MI in control cases
DNA was extracted from serum, peritoneal fluid and paraffin-
embedded cyst wall samples from four patients with benign muci-
nous cystadenoma of the ovary and four with physiological
ovarian corpus luteal cysts, as controls to evaluate the level of false
positive results using this approach. The three samples from each
of eight patients were analysed for alterations at all six loci by
comparison with normal DNA extracted from white blood cells.
Out of a total matrix of 144 genetic analyses, only two displayed
genetic abnormalities; an MI at p53 and an LOH at 522, in the
serum of a patient with a physiological cyst (results not shown).
DISCUSSION
We were able to detect genetic alterations in the free circulating
DNA extracted from the serum of 17/20 (85%) patients with
ovarian carcinoma, using a panel of six microsatellite loci. In addi-
tion, exfoliated cells from 12/19 (63%) peritoneal fluid samples
were found to contain tumour-specific alterations. For such a
limited panel of genetic markers this represents a relatively high
degree of sensitivity. Given that all tumour cell populations will
contain genetic alterations of some description it should be
possible to approach 100% sensitivity using an optimized panel of
genetic markers.
Significantly, it was possible to detect tumour-specific genetic
markers in serum samples from five out of six patients with stage
Ia disease. This suggests that detectable amounts of DNA are
released into the blood from tumours confined to one ovary.
Previous studies have shown that tumour DNA can be detected in
the serum of patients with advanced head and neck (Nawroz et al,
1996), lung (Chen et al, 1996) and colon cancer (Hibi et al, 1998).
Our results clearly demonstrate that the earliest defined stage of
ovarian carcinoma is detectable using this approach.
Surprisingly, one of the control patients with a physiological
cyst had two genetic alterations in her serum DNA which were not
present in her peritoneal fluid or ovarian tissue. Although there
was nothing in this patient’s clinical findings to suggest malig-
nancy, it is feasible that she may have had an occult neoplasm.
Genetic alterations of this type should be highly specific for
tumour cell populations. If the possibility of PCR artefacts are
eliminated, molecular detection techniques used for screening
purposes should theoretically approach 100% specificity.
It is not possible to identify the precise biological or physical
pathways through which DNA from tumour cells can enter the
blood. Tumour cell death can occur through apoptosis, senescence,
necrosis or immunosurveillance, any of which could theoretically
result in tumour DNA entering the blood stream. The relative
contribution of these processes will vary from tumour to tumour,
depending on the phenotype of the cells. For example, it has been
suggested that the MI/RER+ genotype may make cells more
immunogenic, due to accumulation of amino acid alterations in
cell antigens, and therefore better targets for immunosurveillance
(Bicknell et al, 1996). This could explain the improved prognosis
for colorectal cancer patients with this genotype (Lothe et al, 1993;
Lukish et al, 1998). In the case of stage Ia ovarian carcinomas,
which are by definition confined to one ovary, DNA is probably
released directly into the blood stream. With more advanced
disease, exfoliated cells in the peritoneal cavity could provide
another route of entry of DNA into the blood stream via the
lymphatic system.
Our study demonstrates a strong degree of clonality between
serum, exfoliated peritoneal cells and primary tumour DNA.
Nineteen of 26 and 17/18 alterations seen in the serum and peri-
toneal fluid, respectively, were also seen in the corresponding
primary tumour (Figure 1A–C). However, similar studies in head
and neck, lung and colon tumours show almost exclusive clonality
(Chen et al, 1996; Nawroz et al, 1996; Hibi et al, 1998). In our
study we analysed DNA from a single primary tumour block,
usually one showing a preponderance of tumour tissue. Our results
would suggest that in 27% of cases the tumour DNA in the serum
originates from a subpopulation of cells not significantly repre-
sented in the sample microdissected from the primary tumour
paraffin block. Such discrepancies may result from tumour hetero-
geneity and limitations in primary tumour sampling. Another
possibility is that clonal subpopulations of cells carrying specific
changes may undergo preferential cell death and hence be rela-
tively underrepresented in primary ovarian tumours but enriched
for in serum DNA. Previous studies on clonality of ovarian
tumours have not addressed genetic heterogeneity within primary
tumours.
We find a higher frequency of novel alleles in patients with
stage Ia ovarian tumours (3/6) than with stage II–IV (1/14)
(Table 1). This is in agreement with an earlier study by King et al
(1995) who reported that 75% of stage I tumours had MI compared
to 11% of stage II–IV tumours. In addition, LOH is less apparent
in patients with stage Ia tumours (27%) compared to stage II–IV
(57%). This suggests that stage Ia ovarian tumours are more likely
to have an RER+ phenotype than more advanced tumours. Studies
on colorectal carcinoma show that patients with RER+ tumours
have a better prognosis, because of reduced survival for cells with
MI (Lothe et al, 1993; Lukish et al, 1998). In an analogous way the
presence of DNA carrying novel alleles in serum may indicate
higher levels of tumour cell death and signal a better prognosis for
stage Ia ovarian cancer patients.
Two patients with stage Ia disease (3775 and 4224) could tech-
nically be upstaged to stage Ic as a result of tumour DNA being
detected in their peritoneal fluid. These patients had been diag-
nosed as stage Ia on the basis of a negative peritoneal fluid
cytology result and confinement of disease to one ovary
histopathologically. Accurate staging has a significant bearing not
only on prognosis, but also on the possible use of adjuvant
chemotherapy in this patient subgroup. In the case of head and
neck cancer, a prospective multicentre trial is currently underway
in the USA to evaluate the efficacy of molecular staging and its
impact on surgical practice (Caldas, 1997). To our knowledge, this
is the first report of the possible molecular staging of ovarian
cancer.
At present, population-based screening for epithelial ovarian
cancer is not feasible due to the relatively low prevalence (15/
100 000), the lack of specificity of available screening techniques,
the absence of a definitive precursor lesion, and the inability to
determine a lag time for the development of widespread disease.
Advances in transvaginal sonography and colour Doppler imaging
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measurements (Skates et al, 1995) and complimentary serum
markers such as OVX1 (Woolas et al, 1993), have improved early
tumour detection. However, the efficacy of periodic screening of
even high-risk patients has not been clearly established
(Droegemueller, 1994). As molecular detection of tumour DNA in
serum or peritoneal fluid seems possible even in stage Ia disease,
this technique may hold considerable promise as a secondary
screening tool after initial tumour marker or ultrasound abnormal-
ities have suggested ovarian pathology. In terms of disease moni-
toring it will be interesting to observe if and when tumour DNA in
the serum of these patients disappears after treatment, and to what
extent its reappearance in serum predates clinical and biochemical
evidence of recurrence.
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